📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
88 announcements match the current filters (relevance ≥ 5).
Zydus Lifesciences Q4 FY26 Revenue Up 16% YoY; Announces Rs. 11,000 mn Buyback
Zydus Lifesciences Limited reported a strong performance for Q4 FY26 with total revenues from operations growing 16% YoY to Rs. 75,870 mn. EBITDA for the quarter increased by 20% YoY to Rs. 25,544 mn, with margins expanding by 110 bps to 33.7%. Net profit (excluding exceptional items) grew 15% YoY to Rs. 15,929 mn. Additionally, the Board has approved a share buyback of up to Rs. 11,000 mn at Rs. 1,150 per share, representing a 16% premium to the closing price on May 18, 2026.
Key Highlights
Q4 FY26 revenue from operations grew 16% YoY to Rs. 75,870 mn, while full-year FY26 revenue reached Rs. 2,71,484 mn.
EBITDA margin expanded by 110 bps YoY to 33.7% in Q4 FY26, with EBITDA rising 20% YoY to Rs. 25,544 mn.
India formulations business grew 14% YoY to Rs. 17,528 mn, outperforming the market in key chronic therapies.
Board approved a share buyback of up to Rs. 11,000 mn at Rs. 1,150 per equity share.
Signed a definitive agreement to acquire US-based Assertio Holdings Inc. for a consideration of US$ 166 mn.
👀 What to Watch
Investors should view this as a highly positive development given the robust margin expansion, strong domestic growth, and value-accretive buyback at a premium. The acquisition of Assertio Holdings also strengthens the US specialty pipeline, making the stock a strong hold/buy on dips candidate.
Zydus Lifesciences Re-appoints Dr. Sharvil Patel as MD and Appoints Kulin Lalbhai to Board
Zydus Lifesciences has approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five-year term effective from April 1, 2027, ensuring leadership continuity. The board also appointed Mr. Kulin S. Lalbhai, a Harvard MBA and current Director at Arvind Limited, as an Independent Director for a five-year term starting May 19, 2026. These appointments, subject to shareholder approval, aim to strengthen the company's strategic leadership and governance. Dr. Patel has been instrumental in Zydus's recent breakthroughs in complex therapies like NASH treatment.
Key Highlights
Dr. Sharvil P. Patel re-appointed as Managing Director for a 5-year term from April 1, 2027, to March 31, 2032.
Mr. Kulin S. Lalbhai appointed as Independent Director for a 5-year term effective May 19, 2026.
Dr. Patel's leadership has seen Zydus become the first globally to announce a treatment for non-cirrhotic NASH.
Mr. Lalbhai brings extensive experience in digital transformation and consumer-facing businesses from his tenure at Arvind Limited.
Both appointments are subject to shareholder approval via special resolution at the upcoming Annual General Meeting.
👀 What to Watch
Investors should view the leadership continuity and the addition of a high-caliber independent director as a positive sign for long-term governance and strategic execution.
Zydus Lifesciences Approves FY26 Audited Results, Recommends Re. 1 Final Dividend
Zydus Lifesciences has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board has recommended a final dividend of Re. 1 per equity share (100% of face value), pending shareholder approval at the AGM on August 11, 2026. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified audit opinion, indicating no material discrepancies in the financial reporting.
Key Highlights
Recommended a final dividend of Re. 1 per equity share of Re. 1 each (100% payout).
Statutory auditors Deloitte submitted audit reports with an unmodified opinion for FY26.
Annual General Meeting (AGM) is scheduled for Tuesday, August 11, 2026.
Trading window for insiders to reopen on May 22, 2026, following the results announcement.
👀 What to Watch
Investors should examine the detailed financial tables on the company website to assess year-on-year growth in revenue and margins. The dividend provides a steady return, but the stock's movement will likely depend on the underlying earnings growth revealed in the full report.
Zydus Lifesciences Recommends Final Dividend of Rs 1.00 per Share for FY26
Zydus Lifesciences has recommended a final dividend of Rs 1.00 per equity share for the financial year ended March 31, 2026, representing 100% of the face value. This recommendation was made alongside the approval of the company's audited financial results for the quarter and full year. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for August 11, 2026. The statutory auditors, Deloitte, have issued an unmodified opinion on the financial statements, ensuring reporting reliability.
Key Highlights
Recommended a final dividend of Rs 1.00 per equity share (100% of face value)
Annual General Meeting (AGM) for dividend approval set for August 11, 2026
Statutory auditors Deloitte issued an unmodified opinion on FY26 financial results
Trading window for designated persons remains closed until May 21, 2026
👀 What to Watch
Investors should monitor for the announcement of the record date to ensure eligibility for the Rs 1.00 dividend. The unmodified audit report suggests stable financial governance, supporting a long-term hold perspective.
Zydus Lifesciences Approves FY26 Results, Recommends Re. 1 Final Dividend
Zydus Lifesciences has approved its audited financial results for the quarter and fiscal year ended March 31, 2026. The Board has recommended a final dividend of Re. 1 per equity share (100% of face value), pending shareholder approval at the AGM on August 11, 2026. The statutory auditors, Deloitte Haskins & Sells LLP, have issued an unmodified audit opinion, indicating a clean bill of health for the financial statements. The trading window for insiders will reopen on May 22, 2026.
Key Highlights
Recommended a final dividend of Re. 1 per equity share (100% of face value) for FY26
Statutory auditors Deloitte issued an unmodified opinion on both standalone and consolidated results
Annual General Meeting (AGM) scheduled for August 11, 2026, to approve the dividend
Trading window for designated persons to remain closed until May 21, 2026
👀 What to Watch
Investors should review the detailed financial tables on the company's website to evaluate revenue and margin trends. The Re. 1 dividend provides a steady return, but the stock's movement will likely depend on the underlying growth figures in the full report.
Zydus Lifesciences to Acquire US-based Assertio Holdings for $166.4 Million
Zydus Lifesciences, through its subsidiary Zydus Worldwide DMCC, has entered into a definitive agreement to acquire 100% of U.S.-based Assertio Holdings for approximately USD 166.4 million in cash. The acquisition price of USD 23.50 per share provides Zydus with an immediate specialty oncology commercial footprint in the U.S. market. Assertio's primary asset, ROLVEDON®, is a USFDA-approved biologic that generated USD 68.23 million in revenue during CY2025. The transaction is structured as a tender offer followed by a merger and is expected to close in FY 2026-27.
Key Highlights
Total acquisition consideration of approximately USD 166.4 million at USD 23.50 per share in cash.
Acquisition includes ROLVEDON®, a USFDA-approved long-acting G-CSF biologic for cancer patients.
Assertio's ROLVEDON® revenue grew from USD 60.09 million in CY2024 to USD 68.23 million in CY2025.
Provides access to 170+ community oncology accounts and established buy-and-bill infrastructure in the U.S.
The transaction is expected to be completed within the financial year 2026-27 subject to regulatory approvals.
👀 What to Watch
Investors should view this as a significant strategic expansion into the high-margin U.S. specialty oncology segment. Monitor the progress of the tender offer and the integration of Assertio's commercial platform into Zydus's global operations.
Zydus Lifesciences Unit 9 Biologics Plant Receives 7 USFDA Observations
The USFDA conducted a GMP surveillance inspection at Zydus Lifesciences' Unit 9 facility in Ahmedabad from April 27 to May 5, 2026. The inspection concluded with seven observations, though notably, there were no findings related to data integrity. This facility, located at Zydus Biotech Park, is critical for the company's biologics injectable portfolio. The company has committed to addressing these observations expeditiously to ensure continued compliance.
Key Highlights
USFDA GMP surveillance inspection conducted at Unit 9, Zydus Biotech Park, Ahmedabad.
The inspection took place over 9 days from April 27 to May 5, 2026.
Audit concluded with 7 observations but zero data integrity issues.
Company is working closely with the USFDA to address observations expeditiously.
👀 What to Watch
Investors should monitor the nature of the 7 observations and the subsequent USFDA classification (VAI or OAI). While the lack of data integrity issues is positive, the number of observations warrants a cautious watch on potential clearance timelines.
Zydus Lifesciences Subsidiary Acquires 100% Stake in Aptitude Orthopedie for Euro 360,000
Zydus Lifesciences, through its indirect subsidiary Amplitude SAS, has acquired 100% of Aptitude Orthopedie, a French medical equipment distributor. The acquisition, valued at Euro 360,000, aims to internalize commercial capabilities that were previously outsourced to third-party agents. This strategic move is expected to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs in specific French regions. While the deal size is small relative to Zydus's overall operations, it reflects a focus on margin optimization in international markets.
Key Highlights
Acquisition of 100% share capital (5,000 shares) for a cash consideration of Euro 360,000.
Target entity Aptitude Orthopedie reported a turnover of Euro 364,000 for the fiscal year ending June 30, 2025.
Strategic objective to internalize sales capabilities and eliminate third-party commission fees in France.
Aptitude Orthopedie has been an exclusive commercial agent for Zydus's subsidiary in French departments 14 and 50 since 2016.
The transaction was completed on April 30, 2026, with no regulatory approvals required.
👀 What to Watch
This is a minor bolt-on acquisition aimed at improving operational efficiency and margins in the French market. Investors should monitor if similar cost-saving internalizations are planned for other international territories.
Zydus Lifesciences Subsidiary Acquires 100% Stake in Aptitude Orthopedie for Euro 360,000
Zydus Lifesciences, through its indirect subsidiary Amplitude SAS, has acquired 100% of Aptitude Orthopedie, a French medical equipment distributor. The acquisition was completed for a cash consideration of Euro 360,000 to internalize commercial capabilities and eliminate third-party commission fees. Aptitude Orthopedie reported a turnover of Euro 364,000 in FY2025. This strategic move is intended to reduce long-term selling and distribution costs in the French market.
Key Highlights
Acquired 100% share capital of Aptitude Orthopedie for a cash consideration of Euro 360,000
Target entity turnover stood at Euro 364,000 for FY2025 and Euro 380,000 for FY2024
Strategic objective is to eliminate third-party commissions and reduce long-term distribution costs
The target entity specializes in the distribution of medical equipment and was incorporated in 2016
Transaction completed on April 30, 2026, through indirect subsidiary Amplitude SAS
👀 What to Watch
This is a small bolt-on acquisition aimed at improving operational efficiency and margins in the European market. While the deal size is not material to Zydus' overall valuation, it reflects a disciplined approach to streamlining international distribution.
Zydus Lifesciences Gets DCGI Nod for Phase III Trials of Anti-Malarial Drug Zintrodiazine
Zydus Lifesciences has received DCGI approval to initiate two Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate targeting P. falciparum and P. vivax. The trials will involve a total of 1,041 patients across India to evaluate efficacy, safety, and tolerability against drug-resistant strains. This development, in collaboration with Medicines for Malaria Venture (MMV), addresses the global challenge of artemisinin resistance. Successful completion could position Zydus as a leader in next-generation malaria treatments, addressing a market where over 1,80,000 cases were reported in India last year.
Key Highlights
Received DCGI approval for two Phase III trials involving 651 and 390 patients respectively.
Zintrodiazine targets both P. falciparum and P. vivax, including drug-resistant strains.
The drug is being developed as an alternative to current artemisinin-based combination therapies (ACTs).
Collaboration with Medicines for Malaria Venture (MMV) has been ongoing since 2016.
Primary objective is evaluating efficacy via PCR-adjusted adequate clinical and parasitological response (ACPR).
👀 What to Watch
Investors should monitor the progress of these Phase III trials as they represent a significant milestone in Zydus's innovation-led R&D pipeline. Success in these trials could open substantial global market opportunities given the rising resistance to existing malaria treatments.
Zydus Lifesciences Receives USFDA EIR for Ahmedabad Oncology Injectable Facility
Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for its oncology injectable manufacturing facility in SEZ1, Ahmedabad. This follows a Pre-Approval Inspection (PAI) conducted between November 4 and November 13, 2025, specifically for a new isolator injectable line. The successful closure of this inspection clears a major regulatory hurdle for the facility. This approval is expected to support the company's growth in the high-value oncology segment in the US market.
Key Highlights
Received EIR and approval letter from USFDA for the SEZ1 Ahmedabad oncology site
Inspection was a Pre-Approval Inspection (PAI) for a new isolator injectable line
The USFDA audit was conducted over a 10-day period from November 4 to November 13, 2025
Approval facilitates future commercial launches of oncology injectables from this facility
👀 What to Watch
This is a positive regulatory milestone that strengthens Zydus's specialized manufacturing capabilities. Investors should monitor for subsequent ANDA approvals linked to this facility as they will drive future revenue growth.
Zydus Receives USFDA Approval for Dapagliflozin; Targets $10.2bn US Market
Zydus Lifesciences has received final USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), the generic version of Farxiga used for treating Type 2 diabetes. This approval is highly significant as the drug has an annual market size of approximately USD 10.2 billion in the United States. Zydus is also eligible for 180 days of shared generic drug exclusivity, which usually results in higher pricing power and margins during the launch phase. The product will be manufactured at the company's SEZ facility in Ahmedabad, further strengthening its US generic portfolio.
Key Highlights
Final USFDA approval received for Dapagliflozin Tablets (5 mg and 10 mg) for Type 2 diabetes.
Eligible for 180 days of shared generic drug exclusivity in the US market.
Targets a massive US market with annual sales of USD 10.2 billion according to IQVIA MAT February 2026 data.
Production to be localized at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
Zydus now has 436 total USFDA approvals and has filed 505 ANDAs since FY 2003-04.
👀 What to Watch
Investors should view this as a major growth catalyst for Zydus's US business given the multi-billion dollar market size and exclusivity period. Monitor the official launch date and subsequent market share gains in the SGLT2 inhibitor segment.
Zydus Lifesciences Launches Semaglutide at Rs 2,200/Month for Diabetes and Obesity
Zydus Lifesciences has launched generic Semaglutide in India under the brand names SEMAGLYN, MASHEMA, and ALTERME following patent expiry. The drug is approved for both Type 2 Diabetes and Obesity, targeting a massive market of 8.9 crore diabetic adults in India. A key differentiator is the introduction of a reusable multi-dose pen device, which significantly lowers the average monthly therapy cost to approximately Rs. 2,200. This move positions Zydus to capture significant market share in the high-growth GLP-1 segment through aggressive pricing and delivery innovation.
Key Highlights
Launched Semaglutide injection for Type 2 Diabetes and Obesity under three distinct brand names
Introduced a first-in-India reusable multi-dose pen device for which the company holds exclusive rights
Priced the treatment at an average monthly cost of approximately Rs. 2,200, making it highly competitive
Targeting a domestic market of 8.9 crore diabetic adults and a rising obese population
Product will be manufactured at the Zydus Biotech Park in Ahmedabad using a 15mg/3ml cartridge
👀 What to Watch
Investors should monitor the adoption rate of these brands as they represent a major growth lever in the chronic care segment. The competitive pricing and innovative delivery system could lead to significant market share gains in the Indian GLP-1 market.
Zydus Lifesciences Launches Aerolife Mini™, India's First Foldable Inhaler Spacer
Zydus Lifesciences has introduced Aerolife Mini™, a next-generation pMDI enhancer, through an exclusive licensing agreement with AeroDel Technology. The device is India's first portable and foldable spacer, designed to solve the issue where 94% of patients make critical errors using standard inhalers. This launch targets the growing burden of asthma and COPD in India, aiming to improve drug deposition and patient compliance. The move aligns with Zydus' strategy to build a differentiated respiratory franchise using patient-centric drug-device innovations.
Key Highlights
India's first foldable and portable next-gen pMDI enhancer launched under exclusive license.
Targets a critical healthcare gap where 94% of patients make errors in inhaler technique.
Developed in partnership with AeroDel Technology, supported by India's Dept. of Science and Technology.
Part of Zydus' innovation-led strategy involving 1,500 scientists and 29,000 global employees.
👀 What to Watch
This launch strengthens Zydus' position in the high-growth respiratory segment; investors should monitor its impact on the company's domestic formulation margins and market share.
Zydus and Torrent Pharma Partner to Co-Market Semaglutide Injection in India
Zydus Lifesciences and Torrent Pharma have entered into a licensing and supply agreement to co-market an innovative Semaglutide formulation in India. Zydus will manufacture the 15 mg/3 ml injection and receive an upfront licensing fee from Torrent Pharma. The product, administered via a reusable pen, targets Type 2 diabetes and chronic weight management. This partnership leverages Zydus's R&D capabilities and Torrent's extensive distribution network in chronic therapies to capture the high-growth GLP-1 market.
Key Highlights
Zydus developed an innovative 15 mg/3 ml Semaglutide formulation with a patient-friendly reusable pen device.
Torrent Pharma to pay an upfront licensing fee for semi-exclusive rights to market the product under the brand SEMBOLIC.
Zydus will market the product under three brands: SEMAGLYN, MASHEMA, and ALTERME.
The therapy targets adults with Type 2 diabetes and chronic weight management for those with BMI ≥30 or ≥27 with comorbidities.
Torrent Pharma brings a strong field force and Top 5 ranking in Cardiovascular and CNS segments to the partnership.
👀 What to Watch
Investors should view this as a positive development for both companies as they enter the lucrative GLP-1 market in India. Zydus benefits from manufacturing volumes and licensing fees, while Torrent strengthens its leadership in chronic disease management.
Zydus and Lupin Partner to Co-Market Innovative Semaglutide Injection in India
Zydus Lifesciences has entered into a licensing and supply agreement with Lupin to co-market its innovative Semaglutide Injection (15 mg/3 ml) in the Indian market. Under the terms, Lupin will pay Zydus upfront licensing fees and milestone payments for semi-exclusive rights to market the product. This partnership leverages Zydus's product development and Lupin's extensive distribution network to target the high-growth diabetes and weight management segments. The product will be launched under multiple brand names by both companies, featuring a patient-friendly reusable pen device.
Key Highlights
Lupin to pay Zydus upfront licensing fees and milestone-based payments for co-marketing rights.
Product is a 15 mg/3 ml Semaglutide Injection indicated for Type 2 diabetes and chronic weight management.
Zydus will market the product under three brands: SEMAGLYN, MASHEMA, and ALTERME.
Lupin will market the product under two brands: Semanext and Lupin’s Livarise.
Targets obesity management for adults with BMI of 30 kg/m2 or greater, or 27 kg/m2 with comorbidities.
👀 What to Watch
Investors should monitor the revenue contribution from milestone payments and the market share gains in the competitive GLP-1 segment in India. This collaboration strengthens Zydus's domestic portfolio and validates its R&D capabilities in complex injectables.
Zydus Subsidiary Sentynl Licenses Progerinin for Rare Disease; Phase 2A Data Due 1H 2026
Zydus Lifesciences' US subsidiary, Sentynl Therapeutics, has entered into a licensing agreement with Korean firm PRG S&T for Progerinin (SLC-D011), a treatment for the ultra-rare genetic disorder Hutchinson-Gilford Progeria Syndrome (HGPS). The drug candidate has already received FDA Orphan Drug designation and is currently in Phase 2A clinical trials, with results expected by the end of June 2026. Upon meeting specific milestones, Sentynl will acquire full rights to the molecule, making it their second therapy for HGPS. This move strengthens Zydus's presence in the high-value, specialized rare disease market in the United States.
Key Highlights
Sentynl Therapeutics to license and potentially acquire full rights to Progerinin (SLC-D011) for HGPS.
The molecule is currently in Phase 2A clinical trials with data readout expected in 1H 2026.
Progerinin has already been granted Orphan Drug designation by the US FDA.
In animal models, the drug increased lifespan by 8-10 weeks, a significant improvement over the 16.8-week average lifespan in control groups.
The agreement allows Sentynl to immediately advance clinical development and expand its rare disease portfolio.
👀 What to Watch
Investors should monitor the Phase 2A trial results in 1H 2026 as a key catalyst for the specialty pipeline. This acquisition reinforces Zydus's strategy of moving into high-margin, low-competition niche segments in the US market.
Zydus Lifesciences' Desidustat Receives NMPA Approval in China for Renal Anaemia
Zydus Lifesciences' innovative drug Desidustat has received approval from China's NMPA for treating anaemia in Chronic Kidney Disease (CKD) patients. Licensed to China Medical System Holdings (CMS) in 2020, the drug addresses a significant unmet need for over 120 million CKD patients in China. Desidustat is an oral HIF-PHI, offering better compliance than traditional treatments, and has already treated over 100,000 patients in India since its 2022 launch. This approval follows successful Phase III clinical trials that met primary efficacy endpoints for hemoglobin maintenance.
Key Highlights
NMPA approval granted for Desidustat to treat renal anaemia in non-dialysis adult CKD patients in China.
The drug targets a massive patient base of approximately 120 million CKD sufferers in the Chinese market.
Zydus has already successfully treated more than 100,000 patients in India with the drug under the brand Oxemia™.
Phase III trial results showed the drug maintains Hb levels within target ranges with a favorable safety profile.
👀 What to Watch
This regulatory win strengthens Zydus's position in the global innovative drug space and opens a high-volume revenue stream. Investors should monitor the commercial rollout in China and subsequent royalty or milestone income.
Zydus Lifesciences Receives USFDA Approval for Cevimeline Hydrochloride Capsules 30mg
Zydus Lifesciences has received final USFDA approval for Cevimeline Hydrochloride Capsules 30mg, used to treat dry mouth associated with Sjögren’s syndrome. The product will be manufactured at the company's SEZ-II facility in Ahmedabad and targets a market with annual sales of USD 26.9 million as of January 2026. This approval brings the group's total USFDA approvals to 436, reflecting a strong track record in the US generic market. The company has filed a total of 505 ANDAs since the commencement of its filing process in FY 2003-04.
Key Highlights
Final USFDA approval for Cevimeline Hydrochloride Capsules 30mg (Generic for Evoxac®)
Targets an addressable market size of USD 26.9 million according to IQVIA MAT Jan-26 data
Production to be localized at the Group’s manufacturing facility at SEZ-II, Ahmedabad
Total USFDA approvals reach 436 with 505 ANDAs filed as of December 31, 2025
👀 What to Watch
This is a positive incremental development for Zydus's US portfolio; investors should monitor the company's ability to maintain its high rate of ANDA approvals and successful product launches.
Zydus Lifesciences Launches AI-Powered CGM Devices Diasens and GlucoLive
Zydus Lifesciences has expanded its companion diagnostics portfolio with the launch of Diasens and GlucoLive, next-generation AI-powered Continuous Glucose Monitoring (CGM) devices. These devices target India's massive diabetic population of 101 million and 136 million pre-diabetics by offering real-time data streaming every three minutes. The company has partnered with TatvaCare to integrate these devices with the GoodFlip app, providing a comprehensive AI-driven care ecosystem. This launch addresses a critical gap in the Indian market where most glucose monitoring is currently episodic or requires manual scanning.
Key Highlights
Launch of Diasens and GlucoLive CGM devices featuring AI-powered analytics and remote clinician monitoring.
Devices provide automatic data streaming every 3 minutes, removing the need for manual NFC scanning required by competitors.
Targets a massive addressable market in India including 101 million diabetics and 136 million pre-diabetics.
Strategic focus on high-risk segments like Chronic Kidney Disease (CKD) and post-transplant patients.
Partnership with TatvaCare for the GoodFlip app to provide personalized diet, exercise coaching, and medical record storage.
👀 What to Watch
Investors should monitor the market penetration of these devices as they represent a high-growth entry into the digital health and chronic disease management segment. The recurring nature of CGM sensors and the integrated ecosystem could provide long-term revenue stability.
